Xellsmart Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 100

Employees

  • Latest Deal Type
  • Series C1

  • Latest Deal Amount
  • $72.4M

  • Investors
  • 33

Xellsmart General Information

Description

Developer of stem cell treatment solutions intended to improve major disease treatment and drug discovery. The company offers off-the-shelf candidates manufactured to clinical grade with integrated quality control, standardized processes spanning reprogramming and directed differentiation, and regulatory clearances for early-stage studies in Parkinson's disease, spinal cord injury, and amyotrophic lateral sclerosis, providing patients with clinical solutions.

Contact Information

Website
www.xellsmart.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 201, Building 3, Block B, Phase III Biomedical Industrial Park
  • Number 99 Jingu Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Unit 201, Building 3, Block B, Phase III Biomedical Industrial Park
  • Number 99 Jingu Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, Jiangsu 215000
  • China
+86 021

Xellsmart Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xellsmart Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C1) 05-Mar-2026 $72.4M Completed Generating Revenue
11. Later Stage VC 25-Feb-2026 Completed Generating Revenue
10. Later Stage VC (Series C1) 14-Jan-2026 Completed Generating Revenue
9. Early Stage VC 30-May-2025 Completed Generating Revenue
8. Early Stage VC (Series B1) 21-Oct-2024 Completed Generating Revenue
7. Early Stage VC 02-Jun-2023 Completed Generating Revenue
6. Early Stage VC (Series A2) 01-Mar-2023 Completed Generating Revenue
5. Early Stage VC (Series A1) 08-Sep-2022 Completed Generating Revenue
4. Early Stage VC (Series A) 30-Aug-2022 $11.8M $39.3M Completed Generating Revenue
3. Early Stage VC 04-Jan-2022 $15.7M $27.6M Completed Generating Revenue
To view Xellsmart’s complete valuation and funding history, request access »

Xellsmart Patents

  • 27

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 11

    Pending

  • Expiring in next 12 mo

Xellsmart Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026179877-A1 Use of combination therapy for enhancing nk cells in treatment of malignant tumors Pending 27-Feb-2025
WO-2026119300-A1 Use and mechanism of motor nerve progenitor cell population for treating spinal cord injury diseases Pending 06-Dec-2024
EP-4782537-A1 Low-immunogenicity cell expressing mcl1 and preparation method therefor Pending 20-Sep-2023
WO-2025061158-A1 Low-immunogenicity cell expressing mcl1 and preparation method therefor Inactive 20-Sep-2023
WO-2025026225-A1 Kit for inducing differentiation of stem cells into motor neural precursor cells and/or motor neurons and use thereof Inactive 28-Jul-2023 C12N5/0619
To view Xellsmart’s complete patent history, request access »

Xellsmart Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xellsmart Investors (33)

Investor Name Investor Type Holding Investor Since Participating Rounds
BOC Financial Assets Investment Growth/Expansion Minority
Guoxin Venture Capital Management (Shenzhen) Growth/Expansion Minority
Huajin Investment Venture Capital Minority
HaoYue Capital Investment Bank Minority
3Sbio Corporation Minority
You’re viewing 5 of 33 investors. Get the full list »

Ready to get started?

Request a free trial

Xellsmart FAQs

  • When was Xellsmart founded?

    Xellsmart was founded in 2021.

  • Where is Xellsmart headquartered?

    Xellsmart is headquartered in Suzhou, China.

  • What is the size of Xellsmart?

    Xellsmart has 100 total employees.

  • What industry is Xellsmart in?

    Xellsmart’s primary industry is Drug Discovery.

  • Is Xellsmart a private or public company?

    Xellsmart is a Private company.

  • What is Xellsmart’s current revenue?

    The current revenue for Xellsmart is .

  • How much funding has Xellsmart raised over time?

    Xellsmart has raised $156M.

  • Who are Xellsmart’s investors?

    BOC Financial Assets Investment, Guoxin Venture Capital Management (Shenzhen), Huajin Investment, HaoYue Capital, and 3Sbio are 5 of 33 investors who have invested in Xellsmart.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process